Tag: SGLT2
Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
‘I will likely be taking one’: Dialysis, Kind 2 diabetes sufferers say they’re able...
According to the CDC, diabetes and kidney disease are among the top ten causes of death for Ohioans.
...